Ventus Therapeutics Inc.
https://www.ventustx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ventus Therapeutics Inc.
Banner Year For Novo Nordisk At The 18th Annual Scrip Awards
AstraZeneca and Moderna also shone as the pharma, biotech and allied industries came together in London on 30 November to celebrate a year of exceptional achievement at the 18th Annual Scrip Awards, hosted by the actor, comedian and presenter Stephen Mangan.
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice